Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Switzerland Not Applicable (State or other jurisdiction of incorporation or organization) Baarerstrasse 14 6300 Zug, Switzerland Not Applicable (A ...

Exhibit 99.1 CRISPR Therapeutics Provides First Quarter 2025 Financial Results and Announces Positive Top-Line Data from Phase 1 Clinical Trial of CTX310™ Targeting ANGPTL3 -Initial CTX310™ Phase 1 clinical data demonstrates dose-dependent decreases in triglycerides (TG) and low- density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 81% in LDL, with a well-tolerated safety profile; presentation anticipated at a medical meeting in the second half of 2025- -CASGEVY® continues to gain mom ...

Core Insights - CRISPR Therapeutics has reported promising initial Phase 1 clinical data for CTX310™, showing significant dose-dependent reductions in triglycerides (TG) and low-density lipoprotein (LDL), with reductions of up to 82% in TG and 81% in LDL, alongside a well-tolerated safety profile [1][3][7] - The company continues to advance its innovative therapies, including CASGEVY®, which has over 65 authorized treatment centers activated globally and is expected to see significant patient growth in 2025 [1][6][7] - Ongoing clinical trials for CTX320™ and next-generation CAR T product candidates CTX112™ and CTX131™ are on track, with updates anticipated in 2025 [1][3][7] Financial Overview - As of March 31, 2025, the company has a strong balance sheet with approximately $1.86 billion in cash, cash equivalents, and marketable securities [1][18] - For the first quarter of 2025, research and development expenses were $72.5 million, a decrease from $76.2 million in the same period of 2024, while general and administrative expenses rose to $19.3 million from $18.0 million [18] - The net loss for the first quarter of 2025 was $136.0 million, compared to a net loss of $116.6 million in the first quarter of 2024 [18][27] Clinical Development Highlights - CTX310™ targets the ANGPTL3 gene, which is crucial for regulating LDL and TG levels, addressing a significant patient population in the U.S. affected by elevated LDL and TG levels [3][19] - The ongoing Phase 1 trial for CTX310 has shown that doses DL3 and DL4 resulted in reductions of up to 75% in ANGPTL3 levels, with no severe adverse events reported [3][4][7] - CTX320™ is also in a Phase 1 trial targeting the LPA gene, with updates expected in the second quarter of 2025 [1][3][7] Pipeline and Future Prospects - The company is advancing two preclinical programs, CTX340™ for refractory hypertension and CTX450™ for acute hepatic porphyrias, both in IND/CTA-enabling studies [1][3][19] - CASGEVY® has been approved in multiple jurisdictions for treating sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT), with ongoing launches and reimbursement agreements enhancing patient access [1][6][14] - The company plans to present further clinical updates and data at medical meetings in the second half of 2025 [1][7]

Group 1 - Gene therapy stocks, including CRISPR Therapeutics (CRSP) and Intellia Therapeutics (NTLA), experienced significant volatility in Q1 2025, resulting in year-to-date share price declines of -2.82% and -24.19%, respectively [1] - The decline in share prices may be partially linked to the overall instability in the biotechnology sector [1] - The analysis focuses on the potential of novel treatments, particularly in Cell & Gene Therapies (CGT), and their ability to generate returns for shareholders [1]

Group 1: Iovance Biotherapeutics - Iovance Biotherapeutics specializes in cancer treatment and received approval for Amtagvi, a therapy for advanced melanoma, which is the first of its kind for solid tumors [3][4] - The company generated $164.1 million in revenue last year, a significant increase from the previous year when it had minimal revenue [4] - Despite the approval and revenue growth, the stock has underperformed due to market dynamics and the complexity of administering TIL therapies, which take 34 days to manufacture [5] - The stock is currently priced under $4 per share, and the company is pursuing regulatory approvals and label expansions for Amtagvi, which could lead to significant upside potential [6] Group 2: CRISPR Therapeutics - CRISPR Therapeutics develops gene-editing therapies using the CRISPR/Cas9 technique and received approval for Casgevy, the first CRISPR medicine, which treats rare blood disorders [8] - The company has not generated substantial revenue since the approval, as manufacturing ex vivo gene-editing therapies is complex and time-consuming [9] - Casgevy is priced at $2.2 million in the U.S., targeting a market of approximately 58,000 patients with minimal competition, indicating potential for significant revenue once it gains traction [10] - The company has delivered returns comparable to the broader market since its IPO in 2016, and long-term investors may benefit from future breakthroughs in gene-editing products [11][13]

Company Performance - CRISPR Therapeutics AG (CRSP) closed at $39.11, with a daily increase of +1.48%, underperforming the S&P 500's gain of 2.03% [1] - The company's stock has decreased by 1.63% over the past month, which is better than the Medical sector's decline of 8.57% and the S&P 500's drop of 5.07% [1] Earnings Expectations - The upcoming earnings report is expected to show an EPS of -$1.27, reflecting an 11.19% improvement from the same quarter last year [2] - Revenue is anticipated to be $5.24 million, indicating a significant increase of 947.2% compared to the previous year’s quarter [2] Full Year Estimates - For the full year, analysts project an EPS of -$5.09 and revenue of $56.98 million, representing changes of -17.28% and +52.69% respectively from the prior year [3] Analyst Sentiment - Recent changes in analyst estimates suggest a positive outlook for CRISPR Therapeutics AG, indicating optimism regarding the company's business and profitability [4] - The Zacks Rank system, which reflects these estimate changes, currently rates CRISPR Therapeutics AG at 3 (Hold) [6] Industry Context - The Medical - Biomedical and Genetics industry, which includes CRISPR Therapeutics AG, has a Zacks Industry Rank of 79, placing it in the top 32% of over 250 industries [7] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]

Group 1 - CRISPR Therapeutics AG closed at $38.54, reflecting a -1.76% change from the previous day, underperforming compared to the S&P 500's gain of 1.67% [1] - The company has experienced a 4.06% decline in share price over the past month, while the Medical sector and S&P 500 have lost 9.34% and 6.57%, respectively [1] Group 2 - Analysts expect CRISPR Therapeutics AG to report earnings of -$1.27 per share, indicating a year-over-year growth of 11.19%, with revenue projected at $5.24 million, a significant increase of 947.2% compared to the same quarter last year [2] - For the full year, earnings are anticipated to be -$5.09 per share and revenue at $56.98 million, reflecting changes of -17.28% and +52.69% from the previous year [3] Group 3 - Recent changes to analyst estimates for CRISPR Therapeutics AG are important as they reflect the company's business dynamics and potential profitability [4] - The Zacks Rank system, which evaluates estimate changes, indicates that CRISPR Therapeutics AG currently holds a Zacks Rank of 3 (Hold) [6] Group 4 - The Medical - Biomedical and Genetics industry, which includes CRISPR Therapeutics AG, is ranked 77 in the Zacks Industry Rank, placing it in the top 32% of over 250 industries [7] - The top 50% rated industries outperform the bottom half by a factor of 2 to 1, indicating a favorable environment for companies within this industry [7]

Core Insights - The biotech industry presents opportunities for significant returns in short timeframes due to clinical or regulatory advancements, with several companies projected to see substantial share price increases in the next year [1][2] Group 1: CRISPR Therapeutics - CRISPR Therapeutics is a leading gene-editing company that received approval for its therapy Casgevy, the first CRISPR-based medicine, but has struggled with sales post-approval due to complex administration [3][4] - Wall Street's average price target for CRISPR Therapeutics is $84.62, indicating a potential upside of 159%, making it a long-term investment consideration despite short-term volatility [4][5] - The company has a promising pipeline, including potential treatments for type 1 diabetes and cancer, appealing to risk-tolerant investors [5] Group 2: Iovance Biotherapeutics - Iovance Biotherapeutics specializes in cancer therapies using tumor-infiltrating lymphocytes and gained U.S. approval for Amtagvi to treat melanoma, achieving $164.1 million in revenue in 2024 [6][7] - The stock has a price target of $20.91, suggesting a potential upside of 543%, with upcoming regulatory approvals and a large patient base in the U.S. as catalysts for growth [7][8] - Iovance could be an attractive option for patient investors, given its innovative approach and potential for further clinical successes [9] Group 3: Regeneron - Regeneron is a well-established biotech firm facing challenges with its key product Eylea due to competition, but has a price target of $914.55, indicating a 50% upside [10] - A legal battle over Eylea's biosimilar could significantly impact share prices, while the success of Dupixent and a robust pipeline enhance its investment appeal [11][12] - The company has initiated a dividend program and continues share buybacks, reinforcing its position as a strong long-term investment [12] Group 4: Sarepta Therapeutics - Sarepta Therapeutics focuses on gene therapies for rare diseases and recently launched Elevidys, but faced a setback with a patient death linked to liver failure [13][14] - Despite the controversy, the average price target remains at $165.35, suggesting an upside of 182%, contingent on clarifying the cause of the patient's death [14][15] - Given the current uncertainty surrounding Elevidys, caution is advised for potential investors until more information is available [15]

ZUG, Switzerland and BOSTON, April 03, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the 24th Annual Needham Virtual Healthcare Conference on Tue, April 8 at 12:45 p.m. ET. A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at ...

A bad combination compounding for biotech So not only were these stocks slammed by the risk-off mentality in the markets ahead of tariffs coming on April 2, but a key resignation at the Federal Drug Administration (FDA) over the weekend raised questions about the speed and willingness of the agency to approve new drug technologies going forward. The double whammy sent these stocks down much more than the market today. Key FDA regulator Marks abruptly leaves Over the weekend, Dr. Peter Marks, who headed the ...